Kids v Cancer promotes pediatric cancer research by identifying structural impediments at key junctures in the research process – new drugs, tissue donation and access to funding – and developing strategies to address them.
Kids v Cancer won the Peter Drucker Prize for Most Innovative Nonprofit in 2015 and the Fast Company #4 Top 10 Most Innovative Nonprofits in 2016.
We authored and championed the Creating Hope Act Pediatric Priority Review Voucher Program, which was passed into law in 2012 as part of the 2012 FDA Safety and Innovation Act, 21 U.S.C. 360ff. The Creating Hope Act provides a market-based incentive to spur pediatric cancer drug development in the form of pediatric priority review vouchers Since 2012, over $1 billion in vouchers have been sold. The Creating Hope Act was reauthorized by Congress in 2016 as part of 21st Century Cures.
We authored and championed the bipartisan Research to Accelerate Cures and Equity (RACE) for Children Act to update the Pediatric Research Equity Act (PREA) to to require companies developing targeted cancer therapies to develop their drugs for children. RACE for Children Act passed into law on August 18, 2017 as part of the FDA Reauthorization Act (FDARA).
We assist physicians and families of children with cancer applying for compassionate use access to unapproved drugs.
ELIGIBILITY FOR ADULT TRIALS
We are pressing for inclusion of children and teens on adult cancer trials unless there is a scientific and ethical rationale not to include them.
We have an autopsy tissue donation program to facilitate post mortem pediatric CNS tumor tissue to science.
Kids v Cancer successfully requested that September be declared as National Childhood Cancer Awareness Month for each year starting 2010.